Advertisement

Topics

Recent Research Analysts' Ratings Updates for Ovid Therapeutics

12:35 EDT 22 May 2018 | Topix

They set a "buy" rating and a $20.00 price target on the stock. 5/10/2018 - Ovid Therapeutics was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong sell" rating.

Original Article: Recent Research Analysts' Ratings Updates for Ovid Therapeutics

NEXT ARTICLE

More From BioPortfolio on "Recent Research Analysts' Ratings Updates for Ovid Therapeutics"

Advertisement
Quick Search
Advertisement
Advertisement